Stockreport

Roth starts CG Oncology at buy, cites anticipated FDA filing [Seeking Alpha]

CG Oncology, Inc.  (CGON) 
PDF Roth said Phase 3 results for the drug could be released at the Society of Urologic Oncology meeting in early December. It sees an approximately 15% upside and 10% down [Read more]